Rezultati pretraživanja
  1. prije 9 sati

    2/7/20 +0.13%AH VLM-114K Phase 2b presentation at EAHAD February 7, 2020 at 8:30 am – 10:00 am CET.

  2. 5. velj

    bull flag with $2.5 bull flag pole !

  3. 4. velj

    - bioturd with cash

  4. 4. velj
    Odgovor korisniku/ci

    Lol chill Fez. is a $3.13B company, is a $90m company. Hell, has more cash then has market cap. What's the point of trying to tear down at this point?

  5. 4. velj

    Any opinion on and into data readout ?

  6. 4. velj

    CBIO 7.10 MC$85M=Cash $85M Thesis-CBIO trading at a stock price as if going bankrupt, rather then as a company with a recently announced collaboration with a major biotech and having both a phase 3 asset and a phase 2B ...

  7. 3. velj

    moving up into presentation. Surprised market wrote this one off in Hem B

  8. 3. velj
    Odgovor korisniku/ci

    Thanks Dough! Here's the full snippet. Looks like we got good results for all that stayed in the trials, mixed with the one dropout due to site injection reaction

  9. 3. velj

    selling at an absurd market cap, could see it appreciate several fold (an type move)

  10. 3. velj

    Big week ahead 2/3 2/4 2/6 Tecfidera IPR 2/6 SUNFISH 2/7 EAHAD 2/8 wet-AMD 2/8 DME Earnings 2/4 2/5 2/6 2/7

  11. 3. velj

    abstracts EAHA Feb5-7th released,confirming higher peak Factor IX expression levels in 28-day Phase IIb DalcA study than with six-day dosing in Cohort 5 of Phase II program, 2) no anti-drug antibodies (ADAs), 3) one patient withdrew from Phase IIb due injection sitereaction

  12. 2. velj
    Odgovor korisniku/ci

    Are you long ?

  13. 2. velj

    ph1B magrolimab plus avelumab in ovarian cancer Feb6-8 ph2b in heme B Feb 7 earnings after hours Monday

  14. 1. velj

    Figure on Earnings release around 2/15 ish. Wondering if and and Takeda can huddle up on Coagulation research.

  15. 31. sij

    reversal $6.70-$6.8 gap to fill. Data next week and runup play may be over ! For those want to have downside / upside data risk. place you bet accordingly !

  16. 30. sij

    Going through Biogen call right now, found it interesting they spoke of GA (C3, same as ) before the Ionis, Pfizer, CAMP4 gene platform BD deals. has 0 EV and two drugs in clinic with a phase 2B readout next week. Good opportunity

  17. 30. sij

    been long w 5 fig share since (ave) $5 not a big vol until >12 mil intraday, tp: b/o price I consider this part if my future retirement in Naples fl :) yes, it has risks

  18. 30. sij
  19. 30. sij

    this name still in a down trend lower high and lower low down trend channel. likely not going to break the channel before the presentation next week !

  20. 30. sij
    Odgovor korisniku/ci

    is very early - preclinical in 2019-in the correct target -C3- great that Biogen is partnering-which I think further validates C3 - I’m investing in because of its very positive P2 data and 2021 interim P3 readout which & I feel will be positive / both invested

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.